Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.37 | N/A | +16.66% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $4.37 | N/A | +16.66% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management remains positive about future opportunities despite current market challenges. They emphasized the importance of innovation.
Management expressed confidence in the company's long-term growth prospects.
They highlighted ongoing investments in research and development.
Amgen's earnings report shows a strong performance in EPS, exceeding expectations by a notable margin. However, the stock fell by 3.17% in reaction, likely due to the lack of revenue details and no guidance for future performance. Investors may be cautious given the uncertainty in the market.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SAP SE ADR
Oct 26, 2020